Business Context and Reporting Period
Company: Capricor Therapeutics, Inc. (CAPR)
Filing Type: Form 8-K (Current Report)
Report Date: May 13, 2025
Reporting Period: First Quarter ended March 31, 2025
Business Overview: The Company is a Delaware corporation focused on therapeutic development, with principal executive offices in San Diego, California. This filing announces the release of financial results for the quarter ended March 31, 2025.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K. It references a press release (Exhibit 99.1) containing the detailed financial results but does not include the specific numerical data within this document.
- Revenue: Not provided in this text.
- Profit/Loss: Not provided in this text.
- Cash Flow: Not provided in this text.
- Margins: Not provided in this text.
- Debt and Liquidity: Not provided in this text.
Note: Specific financial figures are contained in the attached press release (Exhibit 99.1) and are not present in the filing text provided.
Material Changes
The filing text does not provide specific data to compare current period performance against the prior comparable period. It only confirms the issuance of the Q1 2025 results.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that a corporate update was provided alongside the financial results in the press release, but the content of this update is not included in the text.
Legal Disclaimer: The information furnished under Item 2.02 and Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2025 revenue, net loss, and cash position figures.
- Verify the cash runway and liquidity status as detailed in the full press release, as this is critical for a clinical-stage biopharmaceutical company.
- Check for any updates on clinical trial milestones or regulatory filings mentioned in the "Corporate Update" section of the press release.
- Confirm if there were any changes to capital structure or financing activities during the quarter.